Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

NCT05280717 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
316
Enrollment
INDUSTRY
Sponsor class

Stopped Part C cohort 1 was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes.

Conditions

Interventions

Sponsor

Vir Biotechnology, Inc.

Collaborators